Skip to Main Content

Paper Details

SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Clin Cancer Res
1
2023
CRPC, IFN, NC, NC-STING, NF-B, PARP, PARPi, Prostate Cancer, SPOP, SPOP mutations, SPOP substrate-binding cleft, SPOP-mutant (, SPOPmut, SPOPmut CRPC, SPOPmut) prostate cancer, STING, STING1, STING1 protein, Speckle-type POZ protein, androgen, androgen receptor, cGAS, castrate-resistant prostate cancer, genetically modified cell line models, immunosuppressive NC, macrophage, noncanonical, patients, prostate cancer, prostate cancers, tumor
Author NameAffiliation
Ganiraju C ManyamThe University of Texas MD Anderson Cancer Center
Brian D RobinsonCaryl and Israel Englander Institute for Precision Medicine
Brian D Robinson
Massimo Loda
Massimo LodaSandra and Edward Meyer Cancer Center
Christopher E BarbieriCaryl and Israel Englander Institute for Precision Medicine
Christopher E Barbieri
Christopher E BarbieriSandra and Edward Meyer Cancer Center
Christopher E BarbieriCaryl and Israel Englander Institute for Precision Medicine
Christopher E BarbieriSandra and Edward Meyer Cancer Center
Christopher E Barbieri
Samir M HanashThe University of Texas MD Anderson Cancer Center
Samir M HanashThe University of Texas MD Anderson Cancer Center
  • 1 - 13

Datasets

Release 1.2